Q3-osavuosiraportti
22 päivää sitten‧39 min
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
35,05VWAP
Alin
33,83VaihtoMäärä
2,8 81 961
VWAP
Ylin
35,05Alin
33,83VaihtoMäärä
2,8 81 961
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 7.11. | |
| 2024 Yhtiökokous | 19.8. | |
| 2025 Q2-osavuosiraportti | 8.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Q4-osavuosiraportti | 21.3. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
7.10.7.10.Intressant bolag att följa framöver som visar fin lönsamhet, dagens rapport var något under höga förväntningar och gav enormt stort kursfall. Jag passade på att köpa! EDEN PRAIRIE, Minn. - Sanuwave Health, Inc. (NASDAQ:SNWV) reported preliminary third-quarter revenue between $11.4 million and $11.6 million on Monday, representing the highest quarterly revenue in company history despite falling short of its previous guidance. The company has shown strong momentum, with InvestingPro data showing significant returns over the past week and three months, though financial health indicators suggest careful monitoring is warranted. The wound care product provider’s Q3 revenue increased 22-24% compared to the same period last year and grew 12-14% sequentially from the second quarter. The company has recorded 39-40% revenue growth for the first nine months of 2025 compared to the same period in 2024. According to InvestingPro analysis, while growth is impressive, the company operates with a moderate debt level and faces challenges with short-term obligations exceeding liquid assets. Despite achieving record revenue, Sanuwave missed its previously announced guidance range of $12-$12.7 million. The company cited uncertainty in the wound care market regarding proposed reimbursement changes for certain treatment modalities, particularly skin substitutes and grafts, as a factor affecting sales. "The wound care space has had quite a lot of uncertainty around the proposed reimbursement changes," said CEO Morgan Frank in the press release. "This uncertainty seems to have frozen the market a bit, particularly early in the quarter." The company sold a record number of systems during the quarter, with September marking the highest revenue month in Sanuwave history, according to the statement. Based on third-quarter performance, Sanuwave revised its 2025 annual revenue guidance from $48-$50 million to $44-$46 million. The company noted that reimbursement for its UltraMIST product is not affected by potential changes in allograft reimbursement, and it expects a slight increase in reimbursement for the 97610 code in 2026 compared to 2025. Sanuwave plans to release complete third-quarter results around November 7, 2025. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with additional ProTips and detailed metrics in its Pro Research Report, helping navigate this growing but currently unprofitable company’s potential. In other recent news, Sanuwave Health has made several noteworthy announcements. The company has appointed Daniel Coyle as the new chief operating officer, who previously served as the vice president of engineering and operations. Additionally, Sanuwave Health has refinanced its $27.5 million debt facility through a new secured credit facility from J.P. Morgan, which includes a $23 million four-year term loan and a $5 million two-year revolving credit facility. This refinancing effort is part of the company’s ongoing financial strategy. Moreover, Sanuwave Health received a $5 million cash payment from a third-party licensee for the sale of a patent portfolio related to intravascular shockwave applications. In terms of stock evaluations, Northland initiated coverage on Sanuwave Health with an Outperform rating, highlighting the potential of the company’s UltraMIST System. Roth/MKM also raised its price target for the company to $54, citing strong margin performance in the second quarter of 2025. These developments reflect Sanuwave Health’s dynamic activities and strategic financial maneuvers in recent times.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
22 päivää sitten‧39 min
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 7.10.7.10.Intressant bolag att följa framöver som visar fin lönsamhet, dagens rapport var något under höga förväntningar och gav enormt stort kursfall. Jag passade på att köpa! EDEN PRAIRIE, Minn. - Sanuwave Health, Inc. (NASDAQ:SNWV) reported preliminary third-quarter revenue between $11.4 million and $11.6 million on Monday, representing the highest quarterly revenue in company history despite falling short of its previous guidance. The company has shown strong momentum, with InvestingPro data showing significant returns over the past week and three months, though financial health indicators suggest careful monitoring is warranted. The wound care product provider’s Q3 revenue increased 22-24% compared to the same period last year and grew 12-14% sequentially from the second quarter. The company has recorded 39-40% revenue growth for the first nine months of 2025 compared to the same period in 2024. According to InvestingPro analysis, while growth is impressive, the company operates with a moderate debt level and faces challenges with short-term obligations exceeding liquid assets. Despite achieving record revenue, Sanuwave missed its previously announced guidance range of $12-$12.7 million. The company cited uncertainty in the wound care market regarding proposed reimbursement changes for certain treatment modalities, particularly skin substitutes and grafts, as a factor affecting sales. "The wound care space has had quite a lot of uncertainty around the proposed reimbursement changes," said CEO Morgan Frank in the press release. "This uncertainty seems to have frozen the market a bit, particularly early in the quarter." The company sold a record number of systems during the quarter, with September marking the highest revenue month in Sanuwave history, according to the statement. Based on third-quarter performance, Sanuwave revised its 2025 annual revenue guidance from $48-$50 million to $44-$46 million. The company noted that reimbursement for its UltraMIST product is not affected by potential changes in allograft reimbursement, and it expects a slight increase in reimbursement for the 97610 code in 2026 compared to 2025. Sanuwave plans to release complete third-quarter results around November 7, 2025. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with additional ProTips and detailed metrics in its Pro Research Report, helping navigate this growing but currently unprofitable company’s potential. In other recent news, Sanuwave Health has made several noteworthy announcements. The company has appointed Daniel Coyle as the new chief operating officer, who previously served as the vice president of engineering and operations. Additionally, Sanuwave Health has refinanced its $27.5 million debt facility through a new secured credit facility from J.P. Morgan, which includes a $23 million four-year term loan and a $5 million two-year revolving credit facility. This refinancing effort is part of the company’s ongoing financial strategy. Moreover, Sanuwave Health received a $5 million cash payment from a third-party licensee for the sale of a patent portfolio related to intravascular shockwave applications. In terms of stock evaluations, Northland initiated coverage on Sanuwave Health with an Outperform rating, highlighting the potential of the company’s UltraMIST System. Roth/MKM also raised its price target for the company to $54, citing strong margin performance in the second quarter of 2025. These developments reflect Sanuwave Health’s dynamic activities and strategic financial maneuvers in recent times.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
35,05VWAP
Alin
33,83VaihtoMäärä
2,8 81 961
VWAP
Ylin
35,05Alin
33,83VaihtoMäärä
2,8 81 961
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 7.11. | |
| 2024 Yhtiökokous | 19.8. | |
| 2025 Q2-osavuosiraportti | 8.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Q4-osavuosiraportti | 21.3. |
Datan lähde: Morningstar, Quartr
Q3-osavuosiraportti
22 päivää sitten‧39 min
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 7.11. | |
| 2024 Yhtiökokous | 19.8. | |
| 2025 Q2-osavuosiraportti | 8.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Q4-osavuosiraportti | 21.3. |
Datan lähde: Morningstar, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 7.10.7.10.Intressant bolag att följa framöver som visar fin lönsamhet, dagens rapport var något under höga förväntningar och gav enormt stort kursfall. Jag passade på att köpa! EDEN PRAIRIE, Minn. - Sanuwave Health, Inc. (NASDAQ:SNWV) reported preliminary third-quarter revenue between $11.4 million and $11.6 million on Monday, representing the highest quarterly revenue in company history despite falling short of its previous guidance. The company has shown strong momentum, with InvestingPro data showing significant returns over the past week and three months, though financial health indicators suggest careful monitoring is warranted. The wound care product provider’s Q3 revenue increased 22-24% compared to the same period last year and grew 12-14% sequentially from the second quarter. The company has recorded 39-40% revenue growth for the first nine months of 2025 compared to the same period in 2024. According to InvestingPro analysis, while growth is impressive, the company operates with a moderate debt level and faces challenges with short-term obligations exceeding liquid assets. Despite achieving record revenue, Sanuwave missed its previously announced guidance range of $12-$12.7 million. The company cited uncertainty in the wound care market regarding proposed reimbursement changes for certain treatment modalities, particularly skin substitutes and grafts, as a factor affecting sales. "The wound care space has had quite a lot of uncertainty around the proposed reimbursement changes," said CEO Morgan Frank in the press release. "This uncertainty seems to have frozen the market a bit, particularly early in the quarter." The company sold a record number of systems during the quarter, with September marking the highest revenue month in Sanuwave history, according to the statement. Based on third-quarter performance, Sanuwave revised its 2025 annual revenue guidance from $48-$50 million to $44-$46 million. The company noted that reimbursement for its UltraMIST product is not affected by potential changes in allograft reimbursement, and it expects a slight increase in reimbursement for the 97610 code in 2026 compared to 2025. Sanuwave plans to release complete third-quarter results around November 7, 2025. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with additional ProTips and detailed metrics in its Pro Research Report, helping navigate this growing but currently unprofitable company’s potential. In other recent news, Sanuwave Health has made several noteworthy announcements. The company has appointed Daniel Coyle as the new chief operating officer, who previously served as the vice president of engineering and operations. Additionally, Sanuwave Health has refinanced its $27.5 million debt facility through a new secured credit facility from J.P. Morgan, which includes a $23 million four-year term loan and a $5 million two-year revolving credit facility. This refinancing effort is part of the company’s ongoing financial strategy. Moreover, Sanuwave Health received a $5 million cash payment from a third-party licensee for the sale of a patent portfolio related to intravascular shockwave applications. In terms of stock evaluations, Northland initiated coverage on Sanuwave Health with an Outperform rating, highlighting the potential of the company’s UltraMIST System. Roth/MKM also raised its price target for the company to $54, citing strong margin performance in the second quarter of 2025. These developments reflect Sanuwave Health’s dynamic activities and strategic financial maneuvers in recent times.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
35,05VWAP
Alin
33,83VaihtoMäärä
2,8 81 961
VWAP
Ylin
35,05Alin
33,83VaihtoMäärä
2,8 81 961
Välittäjätilasto
Dataa ei löytynyt